Research programme: estrogen receptor-alpha antagonists - Sumitomo

Drug Profile

Research programme: estrogen receptor-alpha antagonists - Sumitomo

Alternative Names: ER-alpha antagonists research programme - Sumitomo; Estrogen receptor-alpha antagonists - Sumitomo; Research programme: ER-alpha antagonists - Sumitomo; TM 0001; TM 0002

Latest Information Update: 30 Aug 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sumitomo Pharmaceuticals
  • Class
  • Mechanism of Action Estrogen receptor agonists; Estrogen receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Postmenopausal osteoporosis

Most Recent Events

  • 10 Feb 1999 Preclinical development for Postmenopausal osteoporosis in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top